Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 9/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060824 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK1ALOX15NPSR1 | |
| SCHEMBL2060823 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK1ALOX15NPSR1 | |
| SCHEMBL3074427 | 0.84 | MAPK1 (0.72) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL3074425 | 0.84 | MAPK1 (0.72) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL31607558 | 0.81 | MAPK1 (0.68) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL18702769 | 0.81 | MAPK1 (0.68) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL18702772 | 0.81 | MAPK1 (0.68) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL16277504 | 0.78 | KMT2A (0.57) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL12069896 | 0.78 | MEN1 (0.57) | KMT2AMEN1MAPK1NPSR1ALDH1A1 | |
| SCHEMBL28406907 | 0.78 | MEN1 (0.57) | KMT2AMEN1MAPK1ALOX15NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |